Grants and Contributions:
The investment will enable population scale production of pandemic influenza vaccines, support large scale manufacturing for global markets, and establish fill finish capabilities at the Toronto site—allowing end to end production from development to packaging.
Please note this update includes a change to improve standardization of reporting across projects. The end date was updated from the end of the work phase (31 March 2027) to the current end date of (30/06/2039). This is not an extension. The end date now reflects the entirety of the agreement duration, including the benefit phase and residual audit period. The original start date was updated to reflect the correct execution date.
Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services; Facilitate the growth and expansion of firms in Canada; Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.